View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi

Morning Notes : ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB...

: ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB, DEME BB, ARG FP, ZEAL DC

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AkzoNobel: Announces merger of equals with US coatings peer Axalta. EVS: 3Q25 preview. GBL: Sale of half of Umicore stake. IBA: Negative press on poor Proton Therapy results, controversy about Dutch PT centres

Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Livio Luyten
  • Wim Hoste
Wim Hoste
  • Wim Hoste

Akzo Nobel Feedback 3Q results conference call

Below are the highlights of the 3Q25 results conference call. 3Q adjusted EBITDA dropped by 2% y/y and was in line with consensus whilst being 2% below our forecast. Akzo adjusted FY25 adj EBITDA guidance from ‘above €1.48bn' to ‘around €1.48bn' which seems in line with our and consensus forecasts. FY performance is still to be supported by € 170m targeted gross savings. Taking into account the volatile track record and low structural growth, we maintain our Hold rating and €65 TP.

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AkzoNobel: 3Q25 in-line, FY guidance trimmed, €300m provision for Ichthys court case. Gimv: ImCheck Therapeutics checked out. Heineken: 3Q25 trading update; outlook FY25 slightly lowered. KPN: Ziggo 2Gbits internet roll out for c.7m homes by end 2025, full Netherlands by 2026. Randstad: 3Q25 result beats 5%; outlook 4Q25 also beats; strong OPEX performance

Guy Sips ... (+4)
  • Guy Sips
  • Livio Luyten
  • Thomas Couvreur
  • Wim Hoste
Wim Hoste
  • Wim Hoste

Akzo Nobel FIRST LOOK: 3Q adj. EBITDA -2%, FY EBITDA guidance slightly...

3Q adjusted EBITDA dropped by 2% y/y and was in line with consensus whilst being 2% below our forecast. Akzo adjusted FY25 adj EBITDA guidance from ‘above € 1.48bn' to ‘around € 1.48bn' which seems in line with our and consensus forecasts. FY performance is still to be supported by € 170m targeted gross savings. Taking into account the volatile track record and low structural growth, we maintain our Hold rating and € 65 TP.

Stijn Demeester
  • Stijn Demeester

AkzoNobel/3Q25 preview and model update/HOLD

Ahead of AkzoNobel's 3Q25 results, we update our model and trim our 2025F-27F Adj. EBITDA estimates by c.2.5% to reflect slightly softer volume development in 2H25, and mark-to-market of FX. We reiterate our HOLD and €65 per share target price.

Stijn Demeester
  • Stijn Demeester

AkzoNobel/Model update post 2Q25 results/HOLD

We update our estimates to reflect AkzoNobel's 2Q25 results and lower FY Adj. EBITDA guidance, driven by FX changes. We maintain our HOLD rating and €65 per share target price.

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Akzo Nobel: FX drives 2Q25 miss and FY guidance cut. dsm-firmenich: Givaudan 1H25 results. Exor: In talks over Iveco sale. Lotus Bakeries: Peer Lindt & Sprüngli 1H25 results. Proximus: CpaaS peer Sinch 2Q25 results hurt by FX. Signify: 2Q25 Preview, challenges ahead. Var Energi: Promising continuation of dividend. Vopak: Continued story. Wereldhave: Strong operational results, positive market tone, guidance raised. Events Calendar

Stefano Toffano
  • Stefano Toffano
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Hoste
Wim Hoste
  • Wim Hoste

Akzo Nobel FIRST LOOK: 2Q adj EBITDA -2%, FY EBITDA guidance lowered b...

2Q adjusted EBITDA dropped by 2% y/y and came in about 2% below our and consensus forecasts. Akzo lowered FY25 adj EBITDA guidance by c. 5% (from ‘above € 1.55bn' to ‘above € 1.48bn'), attributing the reduction to FX changes. The new guidance calls for an adj EBITDA that would be at least flat, with performance supported by € 170m targeted gross savings. Taking into account the volatile track record and low structural growth, we maintain our Hold rating and € 65 target price.

Stijn Demeester
  • Stijn Demeester

AkzoNobel/2Q25 preview and model update/HOLD

We update our model to reflect recent FX trends and a more cautious view on volumes. We trim our Adj. EBITDA estimates by c.3.5% yet increase our target price to €65 per share from €62, reflecting a higher multiple due to a re-rating of key peer PPG and an improved risk profile following the accretive divestment of AkzoNobel India.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch